Factor X conjugate that promotes FX activation

FX conjugates enhance FX activation by binding to the enzyme precursor, addressing the ineffectiveness of conventional therapies in hemophilia A by increasing thrombin generation and reducing treatment inconvenience and infection risk.

JP7841846B2Active Publication Date: 2026-04-07NOVO NORDISK AS
View PDF 2 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Filing Date
2018-11-15
Publication Date
2026-04-07

AI Technical Summary

Technical Problem

Patients with hemophilia A develop neutralizing antibodies against exogenous coagulation factors, rendering conventional therapies ineffective, and current treatments are inconvenient due to the need for intravenous administration, which increases infection risk, especially in young children.

Method used

Development of FX conjugates, such as antibodies or fragments thereof, that stimulate the activation of FX to FXa by binding to the enzyme precursor rather than activated FXa, thereby increasing the availability of FX for interaction with FIXa and enhancing thrombin generation.

Benefits of technology

The FX conjugates effectively stimulate FX activation, potentially replacing the function of FVIII, reducing bleeding episodes and providing a more convenient treatment option with lower infection risk.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007841846000001
    Figure 0007841846000001
  • Figure 0007841846000002
    Figure 0007841846000002
  • Figure 0007841846000003
    Figure 0007841846000003
Patent Text Reader

Abstract

The present application relates to unique FX-binding molecules, such as antibodies and fragments thereof, that are useful in the treatment of hemophilia.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Bispecific antibody substituting for functional protein

    JP2011137000A

  • Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii

    WO2012067176A1